Enteral Nutrition Product in Mild Acute Pancreatitis

The aim of the study is to evaluate the beneficial effects of the administration of enteral nutrition product with milk proteins, monounsaturated fatty acids and low dextrose equivalent maltodextrin and enriched in eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and medium chain triglycerides (MCT) in patients with mild acute pancreatitis. All this against other specific product. The main objectives of this project are: Comparing the tolerance of both preparations. Comparing the evolution of nutritional status in both groups. Comparing the evolution of inflammatory parameters in both groups

Oral administration of an oligomeric formula with milk proteins, mainly whey protein partially hydrolysate, monounsaturated fatty acids (AGM) and low dextrose equivalent maltodextrin and enriched in polyunsaturated fatty acids (PUFA) of omega-3 series, EPA and DHA, and MCT designed for nutritional support of patients with compromised intestinal function, to maintain or improve nutritional status and reduce the inflammatory response in undernourished patients with mild acute pancreatitis, compared with oligomeric enteral nutrition product, low in fat and rich in glutamine.

Patients of this group will receive 2 packets (76 g) per day of AlitraQ (Abbott) product during 28 days.

T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis.

AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine.

To compare the acceptance and tolerance of both products. To compare the nutritional status in both arms.

To compare the inflammatory parameters evolution in both arms. To evaluate the enteral nutrition complications.

Inclusion Criteria: Patients over 18 with Mild Acute Pancreatitis. Exclusion Criteria: Patients with Several Acute Pancreatitis Patients with life expectancy less than 48 hours. Renal (creatinin > 2,5 mg/dl) or kidney failure (GOT/GPT>2 from laboratory normal value) Patients with diabetes mellitus prior to acute pancreatitis. To take part in another study. Pregnant patients Informed consent absence.